Clinical Trial Update: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

View source ↗

Summary

Expanded access study of RAD001 (everolimus) in patients with metastatic renal cell carcinoma. The study is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (RAD001) (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Renal Cell Cancer | Status: NO_LONGER_AVAILABLE